# Clinical Trials Data EGFR - Document 114

# Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT02125240

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Pathologically confirmed lung adenocarcinoma after surgical resection\n\* Stage II-IIIA disease according to 7th edition of TNM staging\n\* Patients must harbor sensitive EGFR gene mutation (19/21)\n\* Received four cycles of platinum-based adjuvant chemotherapy.There are many different kinds of chemotherapy regimens including vinorelbine, gemcitabine, docetaxel, paclitaxel, pemetrexed plus cisplatin or carboplatin.The first cycle of chemotherapy with cisplatin dose of 75 mg / m2 \u00b1 10% or carboplatin AUC = 5 \u00b1 10% to calculate the dose of chemotherapy\n\nExclusion Criteria:\n\n\* Previous systemic anti-tumor therapy, including chemotherapy or targeted therapy(Including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitor, etc\n\* Presence of metastatic disease\n\* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ\n\* Any unresolved chronic toxicity from previous anticancer therapy\n\* Received antitumor radiation therapy (except for the stage IIIA N2 patients who received adjuvant radiotherapy after surgery)",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, a patient with an EGFR gene mutation could be eligible for the clinical trial, but let's check the criteria to confirm:  
  
\*\*Inclusion Criteria:\*\*  
- The patient must have a pathologically confirmed lung adenocarcinoma after surgical resection.  
- The disease should be stage II-IIIA according to the 7th edition of TNM staging.  
- The patient must have a sensitive EGFR gene mutation in exon 19 or 21.  
- The patient must have received four cycles of platinum-based adjuvant chemotherapy.  
  
\*\*Exclusion Criteria (to be avoided):\*\*  
- Previous systemic anti-tumor therapy, including chemotherapy or targeted therapy (like monoclonal antibodies or small molecule tyrosine kinase inhibitors).  
- Presence of metastatic disease.  
- Previous or co-existing malignancies, unless exempted (basal cell carcinoma or cervical cancer in situ).  
- Unresolved chronic toxicity from previous anticancer therapies.  
- Antitumor radiation therapy, except for stage IIIA N2 patients who received adjuvant radiotherapy post-surgery.  
  
If the patient meets the inclusion criteria and none of the exclusion criteria apply, then they would be eligible for the trial. Specifically, they need to have a sensitive EGFR gene mutation (exon 19 or 21) and satisfy all other conditions stated in the inclusion criteria, while not falling under the exclusions outlined.